GATC Health
Transforming Drug Development With Ai That Mimics Human Physiology

In less than a year, GATC Health has discovered and is developing three drug candidates to treat fentanyl addiction, cocaine addiction and PTSD. A feat that would normally take several years for just one drug was made possible because of GATC’s proprietary AI that models human physiology to predict a drug compound’s success with 88% accuracy—versus the industry standard success rate of less than a 10%. This breakthrough technology is poised to re-invent the way drugs are discovered and significantly reduce the risk, expense and time currently required to develop new prescription medicine.

“Up until now, it’s been almost impossible to predict a potential drug’s success well in advance of expensive and risky human trials,” says Tyrone Lam, COO of GATC Health. “GATC’s AI platform uniquely simulates systems biology to identify the best compounds to treat a wide range of diseases very early in the process—well before potentially wasting hundreds of millions of dollars in lost development.”

By Uniquely Modelling Human Physiology And Biophysics In AI, Gatc Health Can Discover Better Drugs With Much Less Risk, Cost And Time, Potentially Saving Hundreds Of Millions Of Dollars Per Drug

GATC Health is addressing the high cost of medicine with its Multiomics Advanced Technology™ (MAT) drug discovery and development platform. MAT can discover a small, highly-qualified set of compounds in just months, compared to the typical result of thousands of compounds that require years to narrow down. GATC Health can potentially save the pharmaceutical industry billions of dollars by enabling them to focus only on pre-qualified drug candidates versus wasting resources on the majority that are destined to fail.

GATC’s MAT platform surpasses other drug discovery AI technology by simulating human biochemistry’s billions of interactions for accurate and rapid novel target identification, drug discovery, drug development and repurposing of failed drugs. The MAT platform processes and analyzes 400 trillion genetic and multiomic data points in seven minutes and simulates biochemical interactions to accurately predict the response of a pharmaceutical asset to a specific disease. In a triple-blind retrospective study analyzing 14,000 known compounds, MAT accurately identified drug candidates that would have a beneficial effect on human biology with 88% accuracy while spotting failures with 84% accuracy. This is an 11x increase over the current industry lead optimization success rate of approximately 8%.

Reducing Risk in the Drug Discovery Process

Existing AI technology results in thousands – at best many hundreds – of potential compounds that must go through lengthy testing to narrow the field to a small number of quality compounds that have a better chance of becoming a new drug.

The difference between what the AI delivers and the testing that is still required is commonly known as the “AI Gap”.

“Even though there are billion dollar companies using AI to improve drug discovery and development.” says Lam. “GATC goes further to close the AI gap because we deliver a very small set of high-quality compounds in months versus delivering hundreds or thousands of compounds that could require years of additional refining. Our unique method of mimicking human physiology discovers more effective, safer drugs in significantly less time.”

Lower Cost and Higher Efficiency

Typically, years and tens of millions of dollars are spent in the preclinical phase (before submitting an application to the FDA for clinical trials). In addition, if a drug fails Phase 3 human trials, hundreds of millions of dollars and many more years are lost. In as little as three to six months, GATC’s MAT platform assembles lead compounds (in-silico) and rapidly filters thousands of alternatives to deliver a successfully optimized small set of high-quality drug candidates. At the current pace, GATC has the ability to discover and develop as many as 10-12 new drugs in 2024 expanding in following years based on further scaling the platform—each with potential values of hundreds of millions of dollars. Recent deals are demonstrating the value of AI in drug discovery. For example, last year Sanofi signed a deal with Exscientia to use their AI to develop 15 small molecule candidates for possible total payouts of as much as $5.2 billion. Based on over $300 million value per optimized molecule candidate in the Exscientia deal, GATC could produce billions of dollars in value per year from its drug discovery platform.

“Because of the high-stakes binary success/fail business model of drug discovery, using AI to predict success and failure early in the process is a necessity,” says Lam. “GATC‘s ability to predict which compounds are most likely to succeed combined with our capacity to produce ten to twelve new drug candidates each year could produce billions of dollars in potential value.”
Healing vs Treatment

GATC Health’s platform creates multi-target compounds designed to return the body to equilibrium (“homeostasis”) and potentially eliminate the broader spectrum of disease effects. This is the next step in creating medications that do more than simply treat — GATC offers solutions that could truly heal patients. GATC’s goal is to design drugs that can also be used early and prophylactically on patients who have identified risks—therapeutics that not only bring patients back from the brink of devastating illness and possible death, but by mitigating risks, truly extend the quality of life as well as adding to their quantity of years on this earth.

Interpreting the effects of new therapeutics on human biology requires AI that predicts non-obvious pathways, causalities, and outcomes.

GATC’s MAT models the physiology and biophysics of the human body to identify how a potential new drug will likely perform, and simultaneously reduce risk along the development pipeline. MAT can both quantify and rank potential assets in relation to potential efficacy and risk. This reduces the number of drug candidates from thousands or millions, down to a select few that can be tested in vivo, thereby allowing its unique strategy to be realized with a lower cost and higher efficiency.

Success in Pre-clinical Trials

The first set of drugs discovered by GATC Health target fentanyl addiction, cocaine addiction and PTSD. These are in preclinical testing with the fentanyl addiction compound in advanced animal trials with the University of California, Irvine. Due to the advanced discovery methodology used by GATC, animal trials may not be necessary in the future. In fact, the FDA Modernization Act 2.0 signed into law in December 2022, ends an FDA mandate that experimental drugs must be tested on animals before they are used on humans in clinical trials. The new legislation allows emerging technologies, including GATC’s computer modelling, to be used to advance drug leads to human trials without the requirement of animal testing.

The non-addictive compound for the treatment of fentanyl addiction is designed to treat Opioid Use Disorder (OUD) by returning the addicted brain back to its natural, healthy state while maintaining sufficient dopamine levels in the addiction and reward centers to reduce discomfort and agitation. This novel approach will also promote remodeling of the brain limbic system by increasing neuroplasticity, thereby facilitating shifts away from learned addiction patterns of thoughts and behaviour. Discovered using GATC’s MAT platform, the drug mechanism is potentially the first to re-wire and restore the brain and it may have application for the treatment of other neurological diseases, including anxiety, depression and Alzheimer’s.
A Seasoned Team of Innovators

Credit for success in bringing a new AI-based model to the pharma industry goes to GATC Health’s world-class software engineers and scientists. The company’s team are veterans of IBM Watson, Roche, Amgen, MIT, Northrop Grumman and the Human Genome Project. Many of them were instrumental in developing some of the world’s bestknown web-based technologies and AI for large enterprise and government organizations. A stellar board of advisors, including Herb Boyer, co-founder of Genentech, the first biotech company to go public, and Tomas Philipson, former senior economic advisor to the Commissioner of the Food and Drug Administration, support product and business opportunities.

“It’s inevitable that technology will accelerate the development of better therapeutics,” says Lam. “GATC’s team is passionate about a future that creates a longer, healthier and better quality of life for everyone.”